Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $22.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 142.02% from the company’s previous close.

Several other equities research analysts have also recently weighed in on TLX. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Citigroup upped their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen cut shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.13.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $9.09 on Tuesday. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $20.00. The stock’s fifty day moving average price is $7.73 and its two-hundred day moving average price is $8.72. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Telix Pharmaceuticals (NASDAQ:TLX) last posted its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analyst estimates of $421.50 million. Analysts anticipate that Telix Pharmaceuticals will post 0.24 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TLX. Millennium Management LLC bought a new position in shares of Telix Pharmaceuticals in the third quarter worth about $1,883,000. Portland Investment Counsel Inc. lifted its holdings in shares of Telix Pharmaceuticals by 108.0% in the fourth quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after acquiring an additional 138,200 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of Telix Pharmaceuticals by 118.6% in the fourth quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock worth $1,876,000 after acquiring an additional 135,893 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals in the second quarter worth about $975,000. Finally, Quadrature Capital Ltd bought a new position in shares of Telix Pharmaceuticals in the fourth quarter worth about $276,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.